Trial Profile
A Single-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the Onset and Duration of Action of RX-10045 Ophthalmic Solution, 0.09% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2014
Price :
$35
*
At a glance
- Drugs RX 10045 (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Auven Therapeutics
- 12 May 2014 New trial record